2024
Impact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease
Sahyoun L, Fetene J, McMillan C, Protiva P, Al Bawardy B, Gaidos J, Proctor D. Impact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease. Digestive Diseases And Sciences 2024, 69: 1654-1660. PMID: 38466459, DOI: 10.1007/s10620-024-08355-3.Peer-Reviewed Original ResearchSevere COVID-19 infectionInflammatory bowel diseaseCOVID-19 infectionIBD flareIBD therapyCOVID-19 treatmentSingle-center retrospective study of adult patientsMethodsA single-center retrospective studyAdvanced therapiesRetrospective study of adult patientsBowel diseaseStudy of adult patientsInflammatory bowel disease therapyDevelopment of severe COVID-19 infectionSevere COVID-19Acute COVID-19Corticosteroid useNo significant differenceNo therapyAdult patientsSupplemental oxygenPrimary outcomeSecondary outcomesTherapyCorticosteroids
2023
Emerging Therapies for Ulcerative Colitis: Updates from Recent Clinical Trials
AlAmeel T, AlMutairdi A, Al-Bawardy B. Emerging Therapies for Ulcerative Colitis: Updates from Recent Clinical Trials. Clinical And Experimental Gastroenterology 2023, 16: 147-167. PMID: 37609124, PMCID: PMC10441644, DOI: 10.2147/ceg.s375969.Peer-Reviewed Original ResearchManagement of UCToll-like receptor 9Ulcerative colitisAdvanced therapiesSubcutaneous tumor necrosis factor (TNF) inhibitorsPhosphodiesterase 4 inhibitor apremilastTumor necrosis factor inhibitorsInnovative clinical trial designsNecrosis factor inhibitorsRecent clinical trialsProgressive inflammatory disorderClinical trial designFurther drug developmentRemission rateBiologic agentsFactor inhibitorsInflammatory disordersTherapeutic armamentariumReceptor 9Clinical trialsAvailable agentsTrial designTherapyColitisDrug developmentOral Vancomycin Induced and Maintained Clinical and Endoscopic Remission in Ulcerative Colitis and Primary Sclerosing Cholangitis Post-liver Transplantation
Almomen H, Al-Bawardy B. Oral Vancomycin Induced and Maintained Clinical and Endoscopic Remission in Ulcerative Colitis and Primary Sclerosing Cholangitis Post-liver Transplantation. Inflammatory Bowel Diseases 2023, 29: 837-838. PMID: 36888548, DOI: 10.1093/ibd/izad040.Peer-Reviewed Original ResearchOutcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease
Sayed A, Assis D, Silveira M, Deng Y, Ciarleglio M, Gaidos J, Proctor D, Al-Bawardy B. Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease. European Journal Of Gastroenterology & Hepatology 2023, 35: 270-274. PMID: 36708297, DOI: 10.1097/meg.0000000000002510.Peer-Reviewed Original ResearchConceptsPrimary sclerosing cholangitisInflammatory bowel diseasePSC-IBDEndoscopic healingTherapy groupAdvanced therapiesClinical remissionBowel diseaseAcute ascending cholangitisRate of cholangitisSmall bowel involvementThird of patientsAscending cholangitisSclerosing cholangitisAdult patientsBowel involvementSecondary outcomesMedian agePrimary outcomeRetrospective studyHigh riskCholangitisPatientsTherapyLarger study
2017
Endoscopic and Radiographic Assessment of Crohn's Disease
Al-Bawardy B, Hansel SL, Fidler JL, Barlow JM, Bruining DH. Endoscopic and Radiographic Assessment of Crohn's Disease. Gastroenterology Clinics Of North America 2017, 46: 493-513. PMID: 28838411, DOI: 10.1016/j.gtc.2017.05.005.BooksConceptsCrohn's diseaseFavorable long-term outcomeEndoscopic mucosal healingRadiologic scoring systemChronic inflammatory disordersLong-term outcomesObjective measuresRadiologic responseDisease activityClinical improvementMucosal healingClinical symptomsReduced hospitalizationsInflammatory disordersRadiographic assessmentTreatment targetsScoring systemScoring toolDiseaseMore objective measuresTherapyCorticosteroidsHospitalizationComplicationsInflammation